Abstract
Color vision deficiencies (CVDs) indicate potential genetic variations and can be important biomarkers of acquired impairment in many neuro-ophthalmic diseases. However, CVDs are typically measured with insensitive or inefficient tools that are designed to classify dichromacy subtypes rather than track changes in sensitivity. We introduce FInD (Foraging Interactive D-prime), a novel computer-based, generalizable, rapid, self-administered vision assessment tool and applied it to color vision testing. This signal detection theory-based adaptive paradigm computes test stimulus intensity from d-prime analysis. Stimuli were chromatic gaussian blobs in dynamic luminance noise, and participants clicked on cells that contain chromatic blobs (detection) or blob pairs of differing colors (discrimination). Sensitivity and repeatability of FInD Color tasks were compared against HRR, FM100 hue tests in 19 color-normal and 18 color-atypical, age-matched observers. Rayleigh color match was completed as well. Detection and Discrimination thresholds were higher for atypical observers than for typical observers, with selective threshold elevations corresponding to unique CVD types. Classifications of CVD type and severity via unsupervised machine learning confirmed functional subtypes. FInD tasks reliably detect CVD and may serve as valuable tools in basic and clinical color vision science.
Competing Interest Statement
The work is supported by NIH Grant R01 EY029713. FInD is patented & owned by Northeastern University, USA. JS & PJB are founders of PerZeption Inc., to which the FInD method is exclusively licensed. JH declares that no competing interests exist.
Funding Statement
This study was funded by NIH Grant R01 EY029713.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of Northeastern University approved the experiment protocol.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
j.he{at}northeastern.edu
j.skerswetat{at}northeastern.edu
Data Availability
Data produced in the present study are available upon reasonable request to the authors.
